BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26431456)

  • 1. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.
    Duconge J; Ruaño G
    Pharmacogenomics; 2015; 16(15):1685-8. PubMed ID: 26431456
    [No Abstract]   [Full Text] [Related]  

  • 2. Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics.
    Just KS; Schneider KL; Schurig M; Stingl JC; Brockmöller J
    Pharmacogenomics; 2017 Aug; 18(13):1281-1297. PubMed ID: 28776468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of pharmacogenetics in the treatment of migraine.
    Borro M; Guglielmetti M; Simmaco M; Martelletti P; Gentile G
    Pharmacogenomics; 2019 Nov; 20(16):1159-1173. PubMed ID: 31637960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.
    Jaquenoud Sirot E; van der Velden JW; Rentsch K; Eap CB; Baumann P
    Drug Saf; 2006; 29(9):735-68. PubMed ID: 16944962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.
    Reynolds KK; Pierce DL; Weitendorf F; Linder MW
    Per Med; 2017 May; 14(3):221-233. PubMed ID: 29767587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding and preventing drug-drug and drug-gene interactions.
    Tannenbaum C; Sheehan NL
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):533-44. PubMed ID: 24745854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding pharmacogenetics to the clinical laboratory: narrow therapeutic index medications as a place to start.
    Bukaveckas BL
    Arch Pathol Lab Med; 2004 Dec; 128(12):1330-3. PubMed ID: 15578874
    [No Abstract]   [Full Text] [Related]  

  • 10. Considerations of pharmacogenetic testing in children.
    Haga SB; Solomon BD
    Pharmacogenomics; 2016 Jun; 17(9):975-7. PubMed ID: 27248426
    [No Abstract]   [Full Text] [Related]  

  • 11. Application of pharmacogenetics in clinical practice: problems and solutions.
    Baskys A
    J Neural Transm (Vienna); 2019 Jan; 126(1):109-113. PubMed ID: 29922908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
    Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
    Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Importance of pharmacogenetics].
    Bolhuis PA
    Ned Tijdschr Geneeskd; 2001 Jan; 145(1):15-8. PubMed ID: 11198959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of dermatology in pharmacogenomics: drug-induced skin injury.
    Borroni RG
    Pharmacogenomics; 2015; 16(4):401-12. PubMed ID: 25823788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality?
    Vladutiu GD
    Mol Genet Metab; 2008 Jan; 93(1):1-4. PubMed ID: 18054511
    [No Abstract]   [Full Text] [Related]  

  • 17. Whole-genome sequencing in pharmacogenetics.
    Urban TJ
    Pharmacogenomics; 2013 Mar; 14(4):345-8. PubMed ID: 23438878
    [No Abstract]   [Full Text] [Related]  

  • 18. Primun non nocere, polypharmacy and pharmacogenetics.
    Isidoro-García M; Sánchez-Martín A; García-Berrocal B; Román-Curto C
    Pharmacogenomics; 2015 Nov; 16(17):1903-5. PubMed ID: 26554320
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and adverse drug reactions.
    Meyer UA
    Lancet; 2000 Nov; 356(9242):1667-71. PubMed ID: 11089838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.